Evidence map›Paper›PMID 31608985›Full record

ArticleBiotechnology and bioengineering2020

Multiorgan microfluidic platform with breathable lung chamber for inhalation or intravenous drug screening and development.

Paula G Miller, Chen-Yu Chen, Ying I Wang, Emily Gao, Michael L Shuler

Open access · greenAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Breast tumor-on-chip models: From disease modeling to personalized drug screening.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  11. Review
  12. Article
  13. Article
  14. Microphysiological Systems: Design, Fabrication, and Applications.ACS biomaterials science & engineering · 2020
    Article
  15. Review
  16. Modifying and IntegratingFrontiers in bioengineering and biotechnology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Paula G MillerDepartment of Biomedical Engineering, Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York.ORCID 0000-0002-9027-9679
Chen-Yu Chen
Ying I WangDepartment of Biomedical Engineering, Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York.ORCID 0000-0003-0236-5962
Emily Gao
Michael L ShulerDepartment of Biomedical Engineering, Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York.ORCID 0000-0002-4662-317X
Cornell University · US

Funding

Populating MPS database with data from multi-organ, human-on-a-chip microphysiological systemsR44TR001326 · NCATS · HESPEROS, LLC · PI HICKMAN, JAMES J, SHULER, MICHAEL L · 2016 to 2021
$6.5M
National Science Foundation NNCI-1542081NCATS NIH HHS R44 TR001326
6 · The paper itself

Abstract

Efficient and economical delivery of pharmaceuticals to patients is critical for effective therapy. Here we describe a multiorgan (lung, liver, and breast cancer) microphysiological system ("Body-on-a-Chip") designed to mimic both inhalation therapy and/or intravenous therapy using curcumin as a model drug. This system is "pumpless" and self-contained using a rocker platform for fluid (blood surrogate) bidirectional recirculation. Our lung chamber is constructed to maintain an air-liquid interface and contained a "breathable" component that was designed to mimic breathing by simulating gas exchange, contraction and expansion of the "lung" using a reciprocating pump. Three cell lines were used: A549 for the lung, HepG2 C3A for the liver, and MDA MB231 for breast cancer. All cell lines were maintained with high viability (>85%) in the device for at least 48 hr. Curcumin is used to treat breast cancer and this allowed us to compare inhalation delivery versus intravenous delivery of the drug in terms of effectiveness and potentially toxicity. Inhalation therapy could be potentially applied at home by the patient while intravenous therapy would need to be applied in a clinical setting. Inhalation therapy would be more economical and allow more frequent dosing with a potentially lower level of drug. For 24 hr exposure to 2.5 and 25 µM curcumin in the flow device the effect on lung and liver viability was small to insignificant, while there was a significant decrease in viability of the breast cancer (to 69% at 2.5 µM and 51% at 25 µM). Intravenous delivery also selectively decreased breast cancer viability (to 88% at 2.5 µM and 79% at 25 µM) but was less effective than inhalation therapy. The response in the static device controls was significantly reduced from that with recirculation demonstrating the effect of flow. These results demonstrate for the first time the feasibility of constructing a multiorgan microphysiological system with recirculating flow that incorporates a "breathable" lung module that maintains an air-liquid interface.

Indexed as

Lab-On-A-Chip DevicesLungModels, BiologicalA549 CellsCell SurvivalCurcuminDrug Evaluation, PreclinicalEquipment DesignHumansMicrofluidic Analytical TechniquesToxicity TestsUreaCurcuminUreabreathable lung moduleinhalation and intravenous drug deliverymultiorgan physiologic system

Identifiers

PMID31608985
PMCPMC6952570
OpenAlexW2980603219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.